BioSpace News Archive

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT.

Lahey Hospital & Medical Center has acquired the XACT ACE™ Robotic System, for use in its leading Interventional Radiology service. ACE is the world’s first hands-free robotic technology combining advanced image-based procedure planning and navigation with robotic instrument insertion and steering capabilities enabling radiologists to deliver site-specific percutaneous solutions with accuracy, consistency, and efficiency

The American Cancer Society held their 2020 Taste of Hope, an annual event that brings award-winning chefs and Chicago foodies together, to celebrate the charity’s fight against cancer.

Reduces the Complexity of Reporting for Screening and Diagnostic MRI Exams to Deliver Time-Saving and Patient Safety Benefits

AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present at 11:35 a.m. Central time.

The discussion will be moderated by Robert LeBoyer, Managing Director of Equity Research at Ladenburg Thalmann & Co., Inc.

Datavant, the leader in helping healthcare organizations safely connect their data, and EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, announced a strategic partnership in which EVERSANA will use Datavant’s data linking technology to enhance its advanced analytics capabilities.

The National Pharmaceutical Council (NPC) today announced that Michael L. Ryan , PharmD, Senior Vice President, Worldwide Value, Access, Pricing and Health Economics and Outcomes Research at Bristol Myers Squibb (BMS), has been elected Chair of NPC’s Board of Directors for 2020-2021. Dr. Ryan has previously served in several leadersh

Denovo Biopharma, a pioneer in applying precision medicine to development of innovative therapies, today announced that its international Phase 3 registrational study for DB102 has fully enrolled

Bridge Medicines receives $10 million capital infusion from investors Takeda Pharmaceutical Company Ltd., Bay City Capital, and Deerfield